Eradication of acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles

Xi Jiang; Jason Bugno; Chao Hu; Yang Yang; Tobias Herold; Jun Qi; Ping Chen; Sandeep Gurbuxani; Stephen Arnovitz; Jennifer Strong; Kyle Ferchen; Bryan Ulrich; Hengyou Weng; Yungui Wang; Hao Huang; Shenglai Li; Mary Beth Neilly; Richard A. Larson; Michelle M. Le Beau; Stefan K. Bohlander; Jie Jin; Zejuan Li; James E. Bradner; Seungpyo Hong; Jianjun Chen

doi:10.1158/0008-5472.CAN-15-2949

Eradication of acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles

Xi Jiang, Jason Bugno, Chao Hu, Yang Yang, Tobias Herold, Jun Qi, Ping Chen, Sandeep Gurbuxani, Stephen Arnovitz, Jennifer Strong, Kyle Ferchen, Bryan Ulrich, Hengyou Weng, Yungui Wang, Hao Huang, Shenglai Li, Mary Beth Neilly, Richard A. Larson, Michelle M. Le Beau, Stefan K. BohlanderJie Jin, Zejuan Li, James E. Bradner, Seungpyo Hong, Jianjun Chen

Department of Pharmacy

Research output: Contribution to journal › Article › peer-review

39 Citations (Scopus)

Abstract

Acute myeloid leukemia (AML) is a common and fatal form of hematopoietic malignancy. Overexpression and/or mutations of FLT3 have been shown to occur in the majority of cases of AML. Our analysis of a large-scale AML patient cohort (N = 562) indicates that FLT3 is particularly highly expressed in some subtypes of AML, such as AML with t(11q23)/MLL-rearrangements or FLT3-ITD. Such AML subtypes are known to be associated with unfavorable prognosis. To treat FLT3-overexpressing AML, we developed a novel targeted nanoparticle system: FLT3 ligand (FLT3L)-conjugated G7 poly(amidoamine) (PAMAM) nanosized dendriplex encapsulating miR-150, a pivotal tumor suppressor and negative regulator of FLT3. We show that the FLT3L-guided miR-150 nanoparticles selectively and efficiently target FLT3-overexpressing AML cells and significantly inhibit viability/growth and promote apoptosis of the AML cells. Our proof-of-concept animal model studies demonstrate that the FLT3L-guided miR-150 nanoparticles tend to concentrate in bone marrow, and significantly inhibit progression of FLT3-overexpressing AML in vivo, while exhibiting no obvious side effects on normal hematopoiesis. Collectively, we have developed a novel targeted therapeutic strategy, using FLT3L-guided miR-150-based nanoparticles, to treat FLT3-overexpressing AML with high efficacy and minimal side effects.

Original language	English
Pages (from-to)	4470-4480
Number of pages	11
Journal	Cancer Research
Volume	76
Issue number	15
DOIs	https://doi.org/10.1158/0008-5472.CAN-15-2949
Publication status	Published - 2016 Aug 1

Bibliographical note

Funding Information:
J.E. Bradner is the President at Novartis Institute of BioMedical Research. No potential conflicts of interest were disclosed by the other authors. Special thanks to our late mentor and colleague Dr. Janet Rowley for her long-term support. The authors thank Drs. Scott Armstrong, Gregory Hannon, and Lin He for providing retroviral constructs. The authors also thank all participants and recruiting centers of the Acute Myeloid Leukemia Cooperative Group (AMLCG) trials. This work was supported by the NIH R01 grants CA182528, CA178454, and CA127277 (J. Chen), Alex's Lemonade Stand Foundation for Childhood Cancer (J. Chen); Leukemia and Lymphoma Society (LLS) Translational Research Grant (J. Chen), American Cancer Society (ACS) Research Scholar grant (J. Chen), The University of Chicago Committee on Cancer Biology (CCB) Fellowship Program (X. Jiang), LLS Special Fellowship (Z. Li), Gabrielle's Angel Foundation for Cancer Research (J. Chen, Z. Li, X. Jiang, and H. Huang), and the family of Marijanna Kumerich and Leukemia and Blood Cancer New Zealand (S.K. Bohlander). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Publisher Copyright:
©2016 AACR.

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/0008-5472.CAN-15-2949

Cite this

Jiang, X., Bugno, J., Hu, C., Yang, Y., Herold, T., Qi, J., Chen, P., Gurbuxani, S., Arnovitz, S., Strong, J., Ferchen, K., Ulrich, B., Weng, H., Wang, Y., Huang, H., Li, S., Neilly, M. B., Larson, R. A., Le Beau, M. M., ... Chen, J. (2016). Eradication of acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles. Cancer Research, 76(15), 4470-4480. https://doi.org/10.1158/0008-5472.CAN-15-2949

@article{57e3a87d496a46ff9ce96ff596fde3b4,

title = "Eradication of acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles",

abstract = "Acute myeloid leukemia (AML) is a common and fatal form of hematopoietic malignancy. Overexpression and/or mutations of FLT3 have been shown to occur in the majority of cases of AML. Our analysis of a large-scale AML patient cohort (N = 562) indicates that FLT3 is particularly highly expressed in some subtypes of AML, such as AML with t(11q23)/MLL-rearrangements or FLT3-ITD. Such AML subtypes are known to be associated with unfavorable prognosis. To treat FLT3-overexpressing AML, we developed a novel targeted nanoparticle system: FLT3 ligand (FLT3L)-conjugated G7 poly(amidoamine) (PAMAM) nanosized dendriplex encapsulating miR-150, a pivotal tumor suppressor and negative regulator of FLT3. We show that the FLT3L-guided miR-150 nanoparticles selectively and efficiently target FLT3-overexpressing AML cells and significantly inhibit viability/growth and promote apoptosis of the AML cells. Our proof-of-concept animal model studies demonstrate that the FLT3L-guided miR-150 nanoparticles tend to concentrate in bone marrow, and significantly inhibit progression of FLT3-overexpressing AML in vivo, while exhibiting no obvious side effects on normal hematopoiesis. Collectively, we have developed a novel targeted therapeutic strategy, using FLT3L-guided miR-150-based nanoparticles, to treat FLT3-overexpressing AML with high efficacy and minimal side effects.",

author = "Xi Jiang and Jason Bugno and Chao Hu and Yang Yang and Tobias Herold and Jun Qi and Ping Chen and Sandeep Gurbuxani and Stephen Arnovitz and Jennifer Strong and Kyle Ferchen and Bryan Ulrich and Hengyou Weng and Yungui Wang and Hao Huang and Shenglai Li and Neilly, {Mary Beth} and Larson, {Richard A.} and {Le Beau}, {Michelle M.} and Bohlander, {Stefan K.} and Jie Jin and Zejuan Li and Bradner, {James E.} and Seungpyo Hong and Jianjun Chen",

note = "Funding Information: J.E. Bradner is the President at Novartis Institute of BioMedical Research. No potential conflicts of interest were disclosed by the other authors. Special thanks to our late mentor and colleague Dr. Janet Rowley for her long-term support. The authors thank Drs. Scott Armstrong, Gregory Hannon, and Lin He for providing retroviral constructs. The authors also thank all participants and recruiting centers of the Acute Myeloid Leukemia Cooperative Group (AMLCG) trials. This work was supported by the NIH R01 grants CA182528, CA178454, and CA127277 (J. Chen), Alex's Lemonade Stand Foundation for Childhood Cancer (J. Chen); Leukemia and Lymphoma Society (LLS) Translational Research Grant (J. Chen), American Cancer Society (ACS) Research Scholar grant (J. Chen), The University of Chicago Committee on Cancer Biology (CCB) Fellowship Program (X. Jiang), LLS Special Fellowship (Z. Li), Gabrielle's Angel Foundation for Cancer Research (J. Chen, Z. Li, X. Jiang, and H. Huang), and the family of Marijanna Kumerich and Leukemia and Blood Cancer New Zealand (S.K. Bohlander). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Publisher Copyright: {\textcopyright}2016 AACR.",

year = "2016",

month = aug,

day = "1",

doi = "10.1158/0008-5472.CAN-15-2949",

language = "English",

volume = "76",

pages = "4470--4480",

journal = "Cancer Research",

issn = "0008-5472",

number = "15",

}

Jiang, X, Bugno, J, Hu, C, Yang, Y, Herold, T, Qi, J, Chen, P, Gurbuxani, S, Arnovitz, S, Strong, J, Ferchen, K, Ulrich, B, Weng, H, Wang, Y, Huang, H, Li, S, Neilly, MB, Larson, RA, Le Beau, MM, Bohlander, SK, Jin, J, Li, Z, Bradner, JE, Hong, S & Chen, J 2016, 'Eradication of acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles', Cancer Research, vol. 76, no. 15, pp. 4470-4480. https://doi.org/10.1158/0008-5472.CAN-15-2949

TY - JOUR

T1 - Eradication of acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles

AU - Jiang, Xi

AU - Bugno, Jason

AU - Hu, Chao

AU - Yang, Yang

AU - Herold, Tobias

AU - Qi, Jun

AU - Chen, Ping

AU - Gurbuxani, Sandeep

AU - Arnovitz, Stephen

AU - Strong, Jennifer

AU - Ferchen, Kyle

AU - Ulrich, Bryan

AU - Weng, Hengyou

AU - Wang, Yungui

AU - Huang, Hao

AU - Li, Shenglai

AU - Neilly, Mary Beth

AU - Larson, Richard A.

AU - Le Beau, Michelle M.

AU - Bohlander, Stefan K.

AU - Jin, Jie

AU - Li, Zejuan

AU - Bradner, James E.

AU - Hong, Seungpyo

AU - Chen, Jianjun

N1 - Funding Information: J.E. Bradner is the President at Novartis Institute of BioMedical Research. No potential conflicts of interest were disclosed by the other authors. Special thanks to our late mentor and colleague Dr. Janet Rowley for her long-term support. The authors thank Drs. Scott Armstrong, Gregory Hannon, and Lin He for providing retroviral constructs. The authors also thank all participants and recruiting centers of the Acute Myeloid Leukemia Cooperative Group (AMLCG) trials. This work was supported by the NIH R01 grants CA182528, CA178454, and CA127277 (J. Chen), Alex's Lemonade Stand Foundation for Childhood Cancer (J. Chen); Leukemia and Lymphoma Society (LLS) Translational Research Grant (J. Chen), American Cancer Society (ACS) Research Scholar grant (J. Chen), The University of Chicago Committee on Cancer Biology (CCB) Fellowship Program (X. Jiang), LLS Special Fellowship (Z. Li), Gabrielle's Angel Foundation for Cancer Research (J. Chen, Z. Li, X. Jiang, and H. Huang), and the family of Marijanna Kumerich and Leukemia and Blood Cancer New Zealand (S.K. Bohlander). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Publisher Copyright: ©2016 AACR.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Acute myeloid leukemia (AML) is a common and fatal form of hematopoietic malignancy. Overexpression and/or mutations of FLT3 have been shown to occur in the majority of cases of AML. Our analysis of a large-scale AML patient cohort (N = 562) indicates that FLT3 is particularly highly expressed in some subtypes of AML, such as AML with t(11q23)/MLL-rearrangements or FLT3-ITD. Such AML subtypes are known to be associated with unfavorable prognosis. To treat FLT3-overexpressing AML, we developed a novel targeted nanoparticle system: FLT3 ligand (FLT3L)-conjugated G7 poly(amidoamine) (PAMAM) nanosized dendriplex encapsulating miR-150, a pivotal tumor suppressor and negative regulator of FLT3. We show that the FLT3L-guided miR-150 nanoparticles selectively and efficiently target FLT3-overexpressing AML cells and significantly inhibit viability/growth and promote apoptosis of the AML cells. Our proof-of-concept animal model studies demonstrate that the FLT3L-guided miR-150 nanoparticles tend to concentrate in bone marrow, and significantly inhibit progression of FLT3-overexpressing AML in vivo, while exhibiting no obvious side effects on normal hematopoiesis. Collectively, we have developed a novel targeted therapeutic strategy, using FLT3L-guided miR-150-based nanoparticles, to treat FLT3-overexpressing AML with high efficacy and minimal side effects.

AB - Acute myeloid leukemia (AML) is a common and fatal form of hematopoietic malignancy. Overexpression and/or mutations of FLT3 have been shown to occur in the majority of cases of AML. Our analysis of a large-scale AML patient cohort (N = 562) indicates that FLT3 is particularly highly expressed in some subtypes of AML, such as AML with t(11q23)/MLL-rearrangements or FLT3-ITD. Such AML subtypes are known to be associated with unfavorable prognosis. To treat FLT3-overexpressing AML, we developed a novel targeted nanoparticle system: FLT3 ligand (FLT3L)-conjugated G7 poly(amidoamine) (PAMAM) nanosized dendriplex encapsulating miR-150, a pivotal tumor suppressor and negative regulator of FLT3. We show that the FLT3L-guided miR-150 nanoparticles selectively and efficiently target FLT3-overexpressing AML cells and significantly inhibit viability/growth and promote apoptosis of the AML cells. Our proof-of-concept animal model studies demonstrate that the FLT3L-guided miR-150 nanoparticles tend to concentrate in bone marrow, and significantly inhibit progression of FLT3-overexpressing AML in vivo, while exhibiting no obvious side effects on normal hematopoiesis. Collectively, we have developed a novel targeted therapeutic strategy, using FLT3L-guided miR-150-based nanoparticles, to treat FLT3-overexpressing AML with high efficacy and minimal side effects.

UR - http://www.scopus.com/inward/record.url?scp=84982671713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982671713&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-15-2949

DO - 10.1158/0008-5472.CAN-15-2949

M3 - Article

C2 - 27280396

AN - SCOPUS:84982671713

SN - 0008-5472

VL - 76

SP - 4470

EP - 4480

JO - Cancer Research

JF - Cancer Research

IS - 15

ER -

Eradication of acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this